Gonghui Li

Sir Run Run Shaw Hospital — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index4.8kcitations258works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(31), Prostate Cancer Treatment and Research(29), Circular RNAs in diseases(26), RNA modifications and cancer(23), MicroRNA in disease regulation(22)

Publications258 total

Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors
Drug Development Research·2025· 1 cited
Development and prospective validation of a multitarget urine RNA assay for noninvasive detection of urothelial carcinoma
iScience·2025Open Access
Data from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S7 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S4 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Methods Note 1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S4 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S3 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S8 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S2 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S3 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S6 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S7 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S6 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Methods Note 2 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Table S5 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S5 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
Supplementary Fig. S2 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N<sup>6</sup>-Methyladenosine
2025Open Access
page 1 of 13Next →

Frequent Co-authors

Chawnshang Chang(23), Liqun Xia(15), Zeyi Lu(9), Lifeng Ding(9), Shuyuan Yeh(9), Dingwei Xue(8), Jun Qian(8), Danyang Shen(8), Yin Sun(8), Qiming Zheng(8), Huan Wang(7), Ruyue Wang(7), Mingchao Wang(6), Liangliang Ren(6), Junjie Xu(6), Dongrong Yang(6), Minxiao Jiang(5), Yuanlei Chen(5), Chenhao Yu(5), Haiyun Xie(5)